Overview

Safety and Efficacy of CLL1 CAR-T Followed by Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia

Status:
NOT_YET_RECRUITING
Trial end date:
2029-12-20
Target enrollment:
Participant gender:
Summary
This study aims to evaluate whether an innovative combination therapy (CLL1 CAR-T sequential allogeneic hematopoietic stem cell transplantation) is safe, feasible and effective for the treatment of relapsed/refractory acute myeloid leukemia (R/R AML).
Phase:
NA
Details
Lead Sponsor:
Donghua Zhang